Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.54 (overall 0.33) | 0.54 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
Knock down and overexpress ETAA1 in a dopamine neuron, astrocyte and microglia tri-culture; measure a transcriptome-wide state shift (bulk RNA-seq) and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- a transcriptome-wide state shift (bulk RNA-seq)
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves a transcriptome-wide state shift (bulk RNA-seq) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of ETAA1 in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: a transcriptome-wide state shift (bulk RNA-seq); dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- ETAA1 in dopamine neurons, braak+0.37 (p 0.329) → +0.14 (p 0.718)receipt 1057
Swarm cases
receipt 1057: ETAA1 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.351, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.341, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.346, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.36, sign flips 0; without severely affected donors +0.23 (p 0.351, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.84 (p 1.4e-5, n 18) vs +0.23 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ETAA1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ETAA1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.63 p 0.026 (needs p < 0.0012)
Receipts
loading the receipts